Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978 | 0.82 | — | — | |
| Dimethylformamide SCHEMBL4594404 | 0.79 | TSHR (0.60) | TSHR | |
| Hydrochloric Acid SCHEMBL30521236 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL29020067 | 0.78 | — | — | |
| Methyl Alcohol SCHEMBL27604198 | 0.76 | — | — | |
| Dimethylformamide SCHEMBL2145949 | 0.75 | — | — | |
| Dimethylformamide SCHEMBL6607493 | 0.74 | TSHR (0.53) | TSHR | |
| Dimethylformamide SCHEMBL124684 | 0.74 | TSHR (0.53) | TSHR | |
| Acetone SCHEMBL4238945 | 0.74 | LMNA (0.35) | — | |
| Dimethylformamide SCHEMBL2184966 | 0.74 | TSHR (0.53) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952303-A | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2019-06-28 | — | — | CN | disclosed |
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2051966-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | Pfizer Products Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | TSHR 3256/4885 |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | AQP1, GLUL, GATD3 | TSHR 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.